A Phase 4 interventional study of Naltrexone/Bupropion and Placebo in Obesity; Drug and Obesity, Morbid, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by Laval University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Obesity, Morbid with a site in Canada — 7 open to participants now, 10 under way, none of them phase 3. Obesity, Morbid · Canada.
Among the 32 studies in Obesity, Morbid with a site in Canada, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 4, and was the 30th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →7 of the 32 studies in Obesity, Morbid with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–60 · Healthy volunteers
Laval University · Sites in Canada
Ages 18–60
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 57 across the 22 interventional studies, 145 across the 10 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 9 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
3 of the studies in Obesity, Morbid with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05242835Laval UniversityManagement of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery | 2027-01 |
| NCT05120492Nova Scotia Health AuthorityOptimal Management of Extreme Obesity and Severe Knee Osteoarthritis Feasibility Trial | 2027-07 |
| NCT06002906University Health Network, TorontoThe Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery. | 2027-07-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Obesity, Morbid with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.
Researchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.
Participants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 108 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be started one month after sleeve gastrectomie on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects.
Drug: Naltrexone/Bupropion
Patients will be started one month after sleeve gastrectomie on a progressive numbers of matched placebo tablets up to 2 tabs twice a day
Drug: Placebo
Drug pages: NaltrexoneStudies of NaltrexoneNaltrexone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BupropionStudies of BupropionBupropion pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.
Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.
Weight loss
% Excess weight loss
Time frame: baseline to 24 months
Percentage of participant with an Excess Weight Loss above 50%
Time frame: Baseline to 24 months
Resolution of associated comorbidities
Type 2 diabetes, hypertension and dislipidemia
Time frame: Baseline to 24 months
Improvement of Eating behaviors (Food Craving State Questionnaire)
Evaluates severity of cravings using a validated questionnaire. Minimum : 15; Maximum : 75; Higher scores mean a worse outcome.
Time frame: Baseline to 24 months
Improvement of Eating behaviors (Food Craving Trait Questionnaire)
Evaluates severity of cravings using a validated questionnaire. Minimum : 39; Maximum : 234; Higher scores mean a worse outcome.
Time frame: Baseline to 24 months
Decrease in food explicit and implicit wanting and liking food reward.
Decrease in food explicit and implicit wanting and liking food reward assessed by Leeds Food Preference Questionnaire using a computerized behavioural task
Time frame: Baseline to 24 month
Improvement in well-being, mood and Quality of Life (SF-36)
36-item short form survey evaluating quality of life on a scale from 0 to 100, higher scores indicate better quality of life
Time frame: Baseline to 24 months
Improvement in well-being, mood and Quality of Life (QLaval)
Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7, higher scores indicate better quality of life
Time frame: Baseline to 24 months
Improvement in well-being, mood and Quality of Life (HAD questionnaire)
HAD questionnaire includes 14 rated items from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), obtaining two scores (maximum score of each score = 21). Higher scores indicate a worse outcome
Time frame: Baseline to 24 months
Gastro-intestinal side-effects
Gastro-intestinal side-effects assessed by GIQLI questionnaire on a scale from 0 to 144. Higher scores indicate better quality of life
Time frame: Baseline to 24-month
Improvement of Eating behaviors (Binge Eating Scale)
To assess the presence of certain binge eating behaviors that may be indicative of an eating disorder. The higher the score, the more binge eating behaviors is observed. The minimum score is 0 while the maximum score is 46. The final result allows to say if the person has an absent (less than 17), moderate (between 18 and 26) or severe (more than 27) binging level.
Time frame: Baseline to 24 months
Improvement of Eating behaviors (YFAS 2.0)
The YFAS 2.0 was designed to assess food addiction. It assesses the symptoms of food addiction and the resulting distress and impaired functioning. The higher the level of symptoms, the more severe the food addiction. Impaired functioning and distress are scored from 0 to 2. Symptoms are scored from 0 to 11. If the functioning and distress score is 1 and above, the food addiction may be mild (2-3 symptoms), moderate (4-5 symptoms), or severe (6+ symptoms).
Time frame: Baseline to 24 months
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naltrexone · Bupropion